Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy

References

• World Health Organization. Osteoporosis: both health organizations and individuals must act now to avoid an impending epidemic. Press release WHO/58 11 October 1999. Available at: www.who.int/inf-pr-1999/en/pr99-58.html [Last accessed 16 November 2006]
   Google Scholar
• National Osteoporosis Foundation: Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008
   Google Scholar
• Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018-26
   Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   Google Scholar
• Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
   Google Scholar
• Chesnut CH 3rd, Skag A, Christiansen C, et al. Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
   Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
   Google Scholar
• Emkey R. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. Med Gen Med 2004;6:6
   Google Scholar
• Harris ST, Watts NB, Li Z, et al. Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. Curr Med Res Opin 2004;20:757-64
   Google Scholar
• Watts NB, Lindsay R, Li Z, et al. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate. Osteoporos Int 2003;14:437-41
   Google Scholar
• Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8
   Google Scholar
• Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med. 2006;119(4 Suppl 1):S12-17
   Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care 2005;11:449-57
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   Google Scholar
• Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2001;10:42-5
   Google Scholar
• Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7
   Google Scholar
• Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
   Google Scholar
• Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-8
   Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
   Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
   Google Scholar
• van Staa TP, Leufkens HGM, Cooper C. Is persistence to bisphosphonate therapy related only to dosing regimen?. Osteoporos Int 2006;17 (Suppl 1):S77
   Google Scholar
• Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61
   Google Scholar
• Rossini M, Bianchi G, Di Munno O, et al. Treatment of Osteoporosis in clinical Practice (TOP) Study Group. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21
   Google Scholar
• Van Staa TP, Geusens P, Leufkens HGM, et al. Persistence to bisphosphonate treatment in actual clinical practice. European Calcified Tissue Society meeting, June 25-29, 2005, Geneva, Switzerland [abstract P610-Su].
   Google Scholar
• Cooper A, Drake J, Brankin E, PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905.
   Google Scholar
• Weiss TW, Henderson SC, McHorney CA, et al. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007;23:2193-203
   Google Scholar
• Gold DT, Safi W, Trinh H. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 2006;22:2383-91
   Google Scholar
• Weiss TW, von Allmen H, Henderson SC, et al. Persistency rates across weekly and monthly bisphosphonates: results from the IMS health longitudinal prescription database. J Bone Miner Res 2006;21(Suppl 1):S419
   Google Scholar
• IMS Longitudinal Prescription database from IMS Health. Accessed May 2006.
   Google Scholar
• Akesson K, Beusterien K, Hebborn A, et al. Strong patient preference for once-monthly over weekly oral bisphosphonate dosing in postmenopausal osteoporosis. Osteoporos Int 2005;16(Suppl 4): [abstract P622-Su]
   Google Scholar
• Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-903
   Google Scholar
• Benhamou C, Licata AA, Devas V, et al. Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis: the BALTO II study. European Calcified Tissue Society meeting, May 10-14, 2006, Prague, Czech Republic [abstract P350].
   Google Scholar
• Weiss TW, Gold DT, Silverman SL, et al. An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study. Curr Med Res Opin 2006;22:949-60
   Google Scholar
• Walliser JA, Bolge SC, Sen SS. Patients’ preference for osteoporosis medications: PREFER-International. International Society for Clinical Densitometry meeting, February 1-4, 2006, San Diego, CA, USA: [abstract 213].
   Google Scholar
• Walliser J, Bolge S, Sen SS. Patients’ perception of importance of different attributes of osteoporosis medication: results from the PREFER-International study. European Calcified Tissue Society meeting, May 10-14, 2006, Prague, Czech Republic: [abstract P464].
   Google Scholar
• Keen R, Jodar E, Iolascon G, et al. European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency. Curr Med Res Opin 2006;22:2375-81
   Google Scholar
• Koay MA, Walker M, Corner A, et al. Improved patient education and support may enhance adherence to bisphosphonate therapy. European Calcified Tissue Society meeting, May 10-14, 2006, Prague, Czech Republic: [abstract P480].
   Google Scholar
• Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
   Google Scholar
• Roux C, Seeman E, Eastell R, et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 2004;20:433-9
   Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35
   Google Scholar
• Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006;17:922-8
   Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research. ISPOR Medication Compliance and Persistence Special Interest Group: Accomplishments. Available at: www.ispor.org/sigs/MCP_accomplishments.asp [Last accessed May 21, 2007].
   Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   Google Scholar
• Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34
   Google Scholar
• Ayanian JZ. Using administrative data to assess health care outcomes. Eur Heart J 1999;20:1689-91
   Google Scholar
• Britton A, McKee M, Black N, et al. Choosing between randomised and non-randomised studies: a systematic review. Health Technol Assess 1998;2:1-124
   Google Scholar
• McKee M, Britton A, Black N, et al. Methods in health services research. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999;319:312-15
   Google Scholar